The newly synthesized compound DHPEE causes vasorelaxation in rat aortic smooth muscle via a dual mechanism of blocking L-type calcium channels and AT1 receptors.
Answers are grounded in this paper and cite their sources.
DHPEE merits further preclinical testing as a dual-action vasodilator; leaves open translation to human hypertension therapy.
INTRODUCTION: DHPEE is a newly synthesized compound by merging the key structural elements in an angiotensin receptor blocker (Telmisartan) with key structural elements in 1,4- dihydropyridine calcium channel blocker (Nifedipine). In this study, we examined dual calcium channel blocking and AT1 antagonist activity for DHPEE. METHODS: The functional inhibitory characteristics of DHPEE were studied in vitro in rat thoracic aorta preparations precontracted by phenylephrine (1μM) or KCl (80μM) or Ang II in normal or calcium-free solutions. RESULTS: Concentration-dependent significant relaxation was observed in aortic rings precontracted with phenylephrine, KCl or Ang II. The tension increment produced by increasing external calcium was also reduced by DHPEE. DHPEE caused a marked decrease in the maximal contractile response of the vasoactive agents and shifted their concentration-response curves to the right. CONCLUSION: DHPEE possesses dual characteristics and cause vasorelaxation by blocking the L-type calcium channels and blocking Ang II receptors (AT1) in rat aortic smooth muscle.
No takes yet. Share an insight, caveat, or question.
Babaei et al. (2011) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: